The Vanguard Group, Inc. has recently announced that it has increased stake in Aligos Therapeutics Inc (NASDAQ:ALGS) by 2.29%. After grabbing 1.01 million shares, the institutional investor is now in possession of 22600.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 2.50% having worth around $0.61 million. Moreover, Newtyn Management LLC increased its share by 20000.0 to have a control over 0.92 million shares.
Aligos Therapeutics Inc (ALGS) concluded trading on 12/07/23 at a closing price of $0.65, with 2.19 million shares of worth about $1.43 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -40.91% during that period and on Thursday the price saw a loss of about -4.69%. Currently the company’s common shares owned by public are about 39.83M shares, out of which, 32.02M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the ALGS stock and their offered price forecasts bring an average price target of $4.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $7.00 and could fall to a lowest price of $1.00. The stock’s current price level is 83.75% above of average price target set by the analysts, while a rise to estimated low would result in gain of 35.0% for the stock. However, touching the estimated high of $7.00 would mean a gain of 90.71% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 3 times over the past 12 months. They bought 8,726,961 shares in 3 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Aligos Therapeutics Inc Vanguard Total Stock Market ETF is currently holding 0.71 million shares of worth totaling $0.43 million. The company recently came buying 0.0 shares which brought its stake up to 1.76% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after selling 0.14 million shares, have now control over 0.35% of the stake in the company. It holds 15317.0 shares of worth $85323.0.
Aligos Therapeutics Inc (NASDAQ: ALGS) started trading at $0.6401, below -$0.04 from concluding price of the previous day. However, the stock later moved at a day high price of 0.6916, or with a loss of -4.69%. Stock saw a price change of -7.14% in past 5 days and over the past one month there was a price change of -11.68%. Year-to-date (YTD), ALGS shares are showing a performance of -31.79% which decreased to -27.82% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.54 but also hit the highest price of $2.41 during that period. The average intraday trading volume for Aligos Therapeutics Inc shares is 81.46K. The stock is currently trading -4.73% below its 20-day simple moving average (SMA20), while that difference is down -8.21% for SMA50 and it goes to -32.60% lower than SMA200.
The Vanguard Group, Inc. acquired 1.01 million shares of Aligos Therapeutics Inc having value of about $0.61 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 22600.0 shares in the company valued at close to $14690.0, or have control over 2.29% stake in the company. Aligos Therapeutics Inc (NASDAQ: ALGS) currently have 39.83M outstanding shares and institutions hold larger chunk of about 25.50% of that. Holding of mutual funds in the company is about 43.71% while other institutional holders and individual stake holders have control over 44.83% and 3.58% of the stake respectively.
The stock has a current market capitalization of $48.70M and its 3Y-monthly beta is at 2.22. It has Quick Ratio of 3.32 while making debt-to-equity ratio of 0.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALGS, volatility over the week remained 10.92% while standing at 13.62% over the month.
Analysts are in expectations that Aligos Therapeutics Inc (ALGS) stock would likely to be making an EPS of -$0.28 in the current quarter, while forecast for next quarter EPS is -$0.39 and it is -$0.96 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.43 which is -$0.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.51 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 38.22% while it is estimated to increase by 31.29% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Aligos Therapeutics Inc (ALGS)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 2 Wall Street analysts, 1 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on January 06, 2023 offering an Overweight rating for the stock and assigned a target price range of between $2 and $3 to it.
